<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002200</url>
  </required_header>
  <id_info>
    <org_study_id>238M</org_study_id>
    <secondary_id>CNAA3008</secondary_id>
    <nct_id>NCT00002200</nct_id>
  </id_info>
  <brief_title>A Study of 1592U89 in HIV-Infected Adults</brief_title>
  <official_title>A 1592U89 Open-Label Protocol for Adult Patients With HIV-1 Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give 1592U89 to
      HIV-positive adults. This study also examines the influence previous anti-HIV treatment has
      on the effectiveness of 1592U89.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive open-label 1592U89 administered orally in combination with at least one
      other antiretroviral agent that the patient has not previously received.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

        Erythropoietin, G-CSF and GM-CSF.

        Patients must have:

          -  CD4+ cell count &lt; 100 cells/mm3.

          -  HIV-1 RNA &gt; 30,000 copies/ml.

          -  Signed, informed consent from parent or legal guardian for patient under 18 years of
             age.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Renal failure requiring dialysis.

          -  Hepatic failure evident by grade 3/4 hyperbilirubinemia and AST 5 times the upper
             limit of normal.

          -  Documented hypersensitivity to 1592U89.

          -  Serious medical conditions, such as diabetes, congestive heart failure,
             cardiomyopathy, or other cardiac dysfunction, that would compromise the safety of the
             patient.

          -  Participation in or ability to participate in an enrolling study of 1592U89.

        Required:

        At least 2 nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor
        (or intolerance to one protease inhibitor and one NRTI due to trying at least 2 different
        regimens with at least one protease inhibitor).

        Alcohol or illicit drug use that may interfere with the patient's compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glaxo Wellcome Inc</name>
      <address>
        <city>Research Triangle Park</city>
        <state>North Carolina</state>
        <zip>277093398</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>CD4 Lymphocyte Count</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <keyword>abacavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

